Skip to Main Content

Paper Details

Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia.
J Clin Oncol
51
2020
CDAR, Cladribine, HCL, Hairy Cell Leukemia, MRD, PATIENTS, Patients, Rituximab, blood, cladribine, hairy cell leukemia, neutrophil, patients, platelet, purine, rituximab, thrombocytopenia
Author NameAffiliation
Evgeny AronsNational Cancer Institute, National Institutes of Health
Evgeny AronsNational Cancer Institute, National Institutes of Health
Maryalice Stetler-StevensonNational Cancer Institute, National Institutes of Health
Maryalice Stetler-StevensonNational Cancer Institute, National Institutes of Health
Mark RaffeldNational Cancer Institute, National Institutes of Health
Mark RaffeldNational Cancer Institute, National Institutes of Health
Seth M SteinbergNational Cancer Institute, National Institutes of Health
Seth M SteinbergNational Cancer Institute, National Institutes of Health
Robert J KreitmanNational Cancer Institute, National Institutes of Health
Robert J KreitmanNational Cancer Institute, National Institutes of Health
Robert J KreitmanNational Cancer Institute, National Institutes of Health
Robert J KreitmanNational Cancer Institute, National Institutes of Health
  • 1 - 12

Datasets

Release 1.2